MIRA-55 demonstrates favorable oral bioavailability and brain exposure.

MIRA Pharmaceuticals announced successful formulation results for MIRA-55, achieving favorable bioavailability and distribution to target tissues. This milestone supports the validation of the non-opioid candidate's potential as a differentiated pain therapy.